Cost-effectiveness analysis with defined budget: How to distribute resources for the prevention of cardiovascular disease?

Health Policy

Volumn 48, Issue 3, 1999, Pages 155-170

  Lindholm, Lars ^a,b   Hallgren, C G ^a,b   Boman, Kurt ^b   Markgren, Kenth ^b   Weinehall, Lars ^a,b   Ogren J E ^b  

^a Department of Community Health   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

Budget restriction; Cost effectiveness; Decision making

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYPOCHOLESTEROLEMIC AGENT;

ARTICLE; BUDGET; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DIASTOLIC BLOOD PRESSURE; DRUG COST; FEMALE; HUMAN; HYPERTENSION; MALE; MODEL; POPULATION RISK;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BUDGETS; CARDIOVASCULAR DISEASES; CHOLESTEROL; COST-BENEFIT ANALYSIS; FEMALE; HEALTH RESOURCES; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; PREVENTIVE HEALTH SERVICES; RISK FACTORS; SWEDEN; VALUE OF LIFE;

EID: 0032701513     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8510(99)00045-7     Document Type: Article

References (24)

1. Drummond M.F. Allocating resources. Int. J. Tech. Assess. Health Care. 6:1990;77-92.
2. Weinstein M.C. Principles of cost-effective resource allocation in health care organizations. Int. J. Tech. Assess. Health Care. 6:1990;93-103.
3. Johanesson M., Weinstein M.C. On the decision rules of cost-effectiveness analysis. J. Health Econ. 12:1993;459-467.
4. Mason J., Drummond M. Reporting the guidelines for economic studies. Health Econ. 4:1995;85-94.
5. Mason J., Drummond M., Torrance G. Some guidelines on the use of cost effectiveness league tables. Br. Med. J. 306:1993;570-572.
6. Birch S., Gafni A. Cost effectiveness/utility analyses. Do current decision rules leads us to where we want to be? J. Health Econ. 11:1992;279-296.
7. Birch S., Gafni A. Changing the problem to fit the solution: Johannesson and Weinstein's (mis) application of economics to real world problems. J. Health Econ. 12:1993;469-476.
8. Gerard K., Mooney G. Qaly league tables: handle with care. Health Econ. 2:1993;59-64.
9. Williams A. Cost-effectiveness analysis: is it ethical? J. Med. Ethics. 18:1992;7-11.
10. Tengs T.O., Adams M.E., Plisikin J.S., Safran D.G., Siegel J.E., Weinstein M.C. et al. Five hundred life-savings interventions and their cost-effectiveness. Risk Anal. 15:1995;369-390.
11. Gold M.R., Siegel J.E., Russel L.B., Weinstein M.C. Cost-effectiveness in health and medicine. 1996;Oxford University Press, New York.
12. Leidl R.M. Some factors to consider when using the results of economic evaluation studies at the population level. Int. J. Tech Assess. Health Care. 10:1994;467-478.
13. Måttligt förhöjt blodtryck (Moderately elevated blood pressure). 1994;Nordstedts Tryckeri, Stockholm. SBU-rapport nr 121 (in Swedish).
14. Adsjö J, Larsson E, Lindgren C. Excell 5 för ekonomer (Excell 5 for economists). Studentlitteratur, Lund, 1994 (in Swedish).
15. Kannel W.B., Wolf P.A., Garrison R.J. The Framingham study. An epidemiological investigation of cardiovascular disease. 1987;National Institute of Health, Bethesda. NHI Publication No 87-2284.
16. MONICA 10 år. En sammanfattande rapport över MONICA-projektet i norra Sverige (A summary of the 10-year MONICA project in Northern Sweden). Samhällsmedicin, Landstingets kansli, Umeå, 1997 (in Swedish).
17. Hebert P.R., Moser M., Mayer J., Hennekens C.H. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch. Intern. Med. 153:1993;578-581.
18. Shepard J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl. J. Med. 333:1995;1301-1307.
19. Weinehall L, Partnership for Health. On the role of primary health care in a community intervention programme. Medical dissertation nr 531, Umeå University, 1997.
20. Lindholm L., Rosén M., Weinehall L., Asplund K. Cost effectiveness and equity of a community based cardiovascular disease prevention programme in Norsjö, Sweden. J. Epidemiol. Community Health. 50:1996;190-195.
21. Andersson F., Rydén-Bergsten T. Hjärtsvikt kostar (Heart failure costs). Läkartidningen. 94:1997;2828-2830. (in Swedish).
22. Troche C.J., Tacke J., Hinzpeter B., Danner M., Lauterbach K.W. Cost-effectiveness of primary and secondary prevention in cardiovascular diseases. Eur. Heart J. 19:1998;C59-C65.
23. Perkins K.A. Interactions among coronary heart disease risk factors. Ann. Behav. Med. 11:1989;3-11.
24. Drummond M.F., O'Brien B., Stoddardt G.L., Torrance G.W. Methods for the health economic evaluation of health care programmes. 1997;Oxford University Press, Oxford.